Model of Colorectal Cancer for Implementation of the HRMA Method for the Genetic Characterization of Human Pathologies

Safiatou T.G. Coulibaly^1, , Valérie Mbengue Gbonon¹, Flore B. Diplo¹, David Ngolo Coulibaly², Solange Kakou Ngazoa², Aboubacar Sylla² and Mireille Dosso^{1, 2}

¹Genetics and Cancer Laboratory, Molecular Genetics Platform, Institut Pasteur of Cote d’Ivoire, 01 BP 490 Abidjan 01, Cote d’Ivoire

²Molecular Biology Platform, Institut Pasteur of Cote d’Ivoire, 01 BP 490 Abidjan 01, Cote d’Ivoire

Cite this paper:
Safiatou T.G. Coulibaly, Valérie Mbengue Gbonon, Flore B. Diplo, David Ngolo Coulibaly, Solange Kakou Ngazoa, Aboubacar Sylla and Mireille Dosso. Model of Colorectal Cancer for Implementation of the HRMA Method for the Genetic Characterization of Human Pathologies. American Journal of Biomedical Research. 2022; 10(1):14-18. doi: 10.12691/ajbr-10-1-3

Abstract

Context: In developing countries and particularly in Sub-Saharan Africa, access to sequencing techniques is limited. In this context, it is necessary to adopt strategies that will allow researchers to work on molecular genetics and genomics and to allow the greatest number of people to benefit from a precision diagnosis that until now has been outsourced to laboratories in Western countries. The high-resolution curve analysis method (HRMA) for the detection of point mutations in diagnostic choices was evaluated here. Methodology and Results: Using genomic DNA from cell lines, the mutation detection sensitivity of the HRMA method was tested on samples containing different percentages of mutated DNA. The results obtained show that the HRMA method can discriminate wild-type samples from those containing a mutation, even for small amounts of mutated DNA in the sample. Conclusion: For the time being, systematic sequencing of all samples for research and diagnosis is a very expensive strategy in our context. The present evaluation allows to consider molecular genetic and genomic studies as well as molecular diagnosis in two steps: (i) screening of samples by the HRMA method; (ii) sequencing of samples containing a mutation by the Sanger method.

Keywords:
High-resolution melting curve analysis (HRMA) human pathology molecular genetics sequencing Cote d’Ivoire

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	H. Mapesi et D. H. Paris, “Non-Communicable Diseases on the Rise in Sub-Saharan Africa, the Underappreciated Threat of a Dual Disease Burden”, Praxis, vol. 108, no 15, p. 997-1005, nov. 2019.
[2]	A. G. Tesema et al., “How well are non-communicable disease services being integrated into primary health care in Africa: A review of progress against World Health Organization’s African regional targets”, PloS One, vol. 15, no 10, p. e0240984, 2020.
[3]	T. Chikowore, A. B. Kamiza, O. H. Oduaran, T. Machipisa, et S. Fatumo, “Non-communicable diseases pandemic and precision medicine: Is Africa ready?”, EBioMedicine, vol. 65, p. 103260, mars 2021.
[4]	Y. T. Lee, Y. J. Tan, et C. E. Oon, “Molecular targeted therapy: Treating cancer with specificity”, Eur. J. Pharmacol., vol. 834, p. 188-196, sept. 2018.
[5]	L.-Y. Guan et Y. Lu, “New developments in molecular targeted therapy of ovarian cancer”, Discov. Med., vol. 26, no 144, p. 219-229, nov. 2018.
[6]	B. Mf et M. Er, “The emerging clinical relevance of genomics in cancer medicine”, Nat. Rev. Clin. Oncol., vol. 15, no 6, juin 2018.
[7]	L. B. Harrison et N. D. Hanson, “High-Resolution Melting Analysis for Rapid Detection of Sequence Type 131 Escherichia coli”, Antimicrob. Agents Chemother., vol. 61, no 6, mai 2017.
[8]	H. Do, M. Krypuy, P. L. Mitchell, S. B. Fox, et A. Dobrovic, “High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies”, BMC Cancer, vol. 8, p. 142, mai 2008.
[9]	“Diagnostic accuracy of high resolution melting analysis for detection of KRAS mutations: a systematic review and meta-analysis | Scientific Reports”. https://www.nature.com/articles/srep07521 (consulté le 21 janvier 2021).
[10]	M. Skrzypczak-Zielinska et al., “A Simple Method for TPMT and ITPA Genotyping Using Multiplex HRMA for Patients Treated with Thiopurine Drugs”, Mol. Diagn. Ther., vol. 20, no 5, p. 493-499, 2016.
[11]	“A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing | BMC Cancer | Full Text”. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2589-2 (consulté le 21 janvier 2021).
[12]	M. Chomarat et F. Breysse, “Technique d’analyse des courbes de fusion haute résolution (FHR) ou High Resolution Melting analysis (HRM) en infectiologie”, Immuno-Anal. Biol. Spéc., vol. 26, no 4, p. 207-211, août 2011.
[13]	R. H. A. M. Vossen, E. Aten, A. Roos, et J. T. den Dunnen, “High-resolution melting analysis (HRMA): more than just sequence variant screening”, Hum. Mutat., vol. 30, no 6, p. 860-866, juin 2009.
[14]	S. Y. C. Tong et P. M. Giffard, “Microbiological Applications of High-Resolution Melting Analysis”, J. Clin. Microbiol., vol. 50, no 11, p. 34183421, nov. 2012.
[15]	I. Simko, “High-Resolution DNA Melting Analysis in Plant Research”, Trends Plant Sci., vol. 21, no 6, p. 528537, juin 2016.